WO2001092215A3 - Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same - Google Patents

Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same Download PDF

Info

Publication number
WO2001092215A3
WO2001092215A3 PCT/US2001/017868 US0117868W WO0192215A3 WO 2001092215 A3 WO2001092215 A3 WO 2001092215A3 US 0117868 W US0117868 W US 0117868W WO 0192215 A3 WO0192215 A3 WO 0192215A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
superoxide
generating
methods
compositions
Prior art date
Application number
PCT/US2001/017868
Other languages
French (fr)
Other versions
WO2001092215A2 (en
Inventor
Challice Bonifant
Joseph Saavedra
Larry Keefer
Michael Citro
Gregory Buzard
Anthony Fitzhugh
Paul Donovan
Xinhua Ji
Paul Shami
Shivendra Singh
Aloka Srinivasan
Original Assignee
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services filed Critical The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Priority to AU2001275155A priority Critical patent/AU2001275155A1/en
Publication of WO2001092215A2 publication Critical patent/WO2001092215A2/en
Publication of WO2001092215A3 publication Critical patent/WO2001092215A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/08—Azoxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Abstract

The invention provides a compounds comprising a [N(O)NO] functional group and a superoxide-generating moiety, wherein said compound is capable of generating nitric oxide and superoxide. The invention also provides compositions comprising same and methods of using same.
PCT/US2001/017868 2000-06-02 2001-06-01 Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same WO2001092215A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001275155A AU2001275155A1 (en) 2000-06-02 2001-07-01 Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20906700P 2000-06-02 2000-06-02
US60/209,067 2000-06-02

Publications (2)

Publication Number Publication Date
WO2001092215A2 WO2001092215A2 (en) 2001-12-06
WO2001092215A3 true WO2001092215A3 (en) 2002-06-27

Family

ID=22777186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017868 WO2001092215A2 (en) 2000-06-02 2001-06-01 Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same

Country Status (2)

Country Link
AU (1) AU2001275155A1 (en)
WO (1) WO2001092215A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9399612B2 (en) 2008-09-10 2016-07-26 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US9447006B2 (en) 2005-06-01 2016-09-20 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041902A1 (en) * 2000-11-27 2002-05-30 The University Of Akron Treatment of disorders using polyethylenimine diazeniumdiolate
WO2003080039A1 (en) 2002-03-21 2003-10-02 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
AU2003234510A1 (en) 2002-05-07 2003-11-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
CA2555591C (en) * 2004-02-09 2011-01-04 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US20080305082A1 (en) * 2004-09-14 2008-12-11 Curd John G 1,4-Bis-N-Oxide-5,8- Dihydroxyanthracenedione Compounds and the Use Thereof
SI1933821T1 (en) 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
DE102007035323A1 (en) 2007-07-25 2009-01-29 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- New diazen-1-ium-1,2-diolate substituted ketoconazole derivatives are ergosterol biosynthesis inhibitors useful as an active agent against microbial pathogenic germs, e.g. fungus, and an antiinflammatory active agent
CN102014870A (en) 2008-03-07 2011-04-13 犹他州大学研究基金会 Activated nitric oxide donors and methods of making and using thereof
KR101351130B1 (en) 2012-11-05 2014-01-15 포항공과대학교 산학협력단 Method for preparing coating film containing nitrogen monoxide using catecholamines in the surface of materials
CN108712903A (en) 2015-12-17 2018-10-26 生物电子技术有限公司 Fluoroalkyl, fluoroalkyl, phenoxy group, heteroaryloxy, alkoxy and amine 1,4- quinone derivatives for treating oxidation emergency obstacle
CN109053618B (en) * 2018-02-22 2022-05-13 青岛科技大学 Preparation method of oxazole derivative
CN112939886B (en) * 2021-02-04 2022-05-31 山西大学 Near-infrared fluorescent probe capable of detecting content of GSTs (glutathione S-terminal transferase) as well as synthetic method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
WO1998013358A1 (en) * 1996-09-27 1998-04-02 The United States Of America Represented By The Secretary, Department Of Health And Human Services O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
WO1998013358A1 (en) * 1996-09-27 1998-04-02 The United States Of America Represented By The Secretary, Department Of Health And Human Services O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447006B2 (en) 2005-06-01 2016-09-20 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9399612B2 (en) 2008-09-10 2016-07-26 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics

Also Published As

Publication number Publication date
WO2001092215A2 (en) 2001-12-06
AU2001275155A1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
WO2001092215A3 (en) Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
GB0013407D0 (en) Forms of a chemical compound
AU2001262475A1 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
WO1999001427A3 (en) Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
WO2002048147A3 (en) Pyrazolopyridines
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
WO2001072702A3 (en) Amidino compounds useful as nitric oxide synthase inhibitors
AU2001283124A1 (en) Generic finger architecture for spread spectrum applications
WO2002006160A3 (en) Methods of synthesizing an oxidant and applications thereof
WO2002100353A3 (en) Cd10-activated prodrug compounds
GB0011203D0 (en) Chemical compounds
WO2002004444A3 (en) Heterocycle carboxamides as antiviral agents
WO2002004443A3 (en) Heterocycle carboxamides as antiviral agents
AU2002306613A1 (en) Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent
WO2002048148A3 (en) Pyrazolopyridine derivatives
AU2324100A (en) Positive resist composition of chemical amplification type
EP1295879A4 (en) Medicinal compositions containing propenone derivatives
WO2002085291A3 (en) Nociceptin analogs
AU2002221853A1 (en) Oxabicyclo(2.2.1)heptane derivatives as pesticidal agents
AU4274001A (en) Chemical amplification type positive resist composition
WO2002040016A8 (en) Association of calpain inhibitors and reactive oxygen species trapping agents
WO2001082874A3 (en) A medicinal aerosol formulation
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2001066144A3 (en) Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP